Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus TRANEXAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID IN PLASTIC CONTAINER versus TRANEXAMIC ACID.
AMINOCAPROIC ACID IN PLASTIC CONTAINER vs TRANEXAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminocaproic acid is a lysine analog that binds to plasminogen and prevents its conversion to plasmin, thereby inhibiting fibrinolysis and stabilizing clots. It also inhibits plasmin directly at high doses.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
4-5 g IV over 1 hour followed by 1 g/h IV for 8 hours or until bleeding is controlled; max 30 g/24h.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
None Documented
None Documented
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateTranexamic acid + Diethylstilbestrol
Terminal elimination half-life is approximately 2-3 hours in patients with normal renal function. In end-stage renal disease, half-life may be prolonged to 7-10 hours.
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Primarily renal (approximately 80-90% excreted unchanged in urine via glomerular filtration).
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antifibrinolytic
Antifibrinolytic
"Tranexamic acid may increase the thrombogenic activities of Diethylstilbestrol."